SOLID-TIMI 52 was a randomized, double-blind, placebo-controlled trial to assess the efficacy of darapladib, a novel Lp-PLA2 inhibitor, when added to standard of care in high-risk patients stabilized after ACS. MAIN RESULTS:Rivaroxaban in patients with a recent acute coronary syndromeN Engl J Med. 2012 Jan 5;366(1):9-19. PRESENTATIONS TIMI 52 SlidesSOLID Ceramides (Gencer, AHA 2019)A Novel … Continue reading SOLID-TIMI 52